By the end of 2020, domestic pharmaceutical manufacturers can maintain sales volumes of 2019 in monetary terms, said President of the Association of Manufacturers of Medications of Ukraine (AMMU) Petro Bahriy.
“The pharmaceutical industry doesn’t have deep minuses in its output, I think that in monetary terms we will reach the same volumes as in 2019, even with a slight plus,” he said in an interview with Interfax-Ukraine.
At the same time, Bahriy noted that significant changes have taken place within the portfolio of domestic pharmaceutical manufacturers, taking into account the fact that hospitals were closed for planned operations for a significant part of the year.”
“The assortment, which provides for planned operations, has decreased, but the anticovid group has grown and there is an increase,” he said.
At the same time, Bahriy called the great success of 2020 that domestic pharmaceutical companies have preserved and developed their exports.
He also stressed that if you take the American protocol for the prevention and treatment of COVID-19, then many of the products included in it are produced in Ukraine – and these drugs “work great.”
The Ukrainian Intellectual Property Institute (Ukrpatent) issued 239 patents for inventions and useful models in the processing industry in 2017, including 42 in the sphere of production of key pharmaceutical products and medicines, which is the largest figure in the past five years. Ukrpatent told Interfax-Ukraine that in 2016, Ukrpatent issued 29 patents to national producers in the sphere of pharmaceutical production, 10 in 2015, seven in 2014 and 19 in 2013.
In January-March 2018, Ukrpatent issued 61 patents for inventions and utility models in the processing industry, including five in production of basic pharmaceutical products and medicines. In the first quarter of 2016 and 2017 in the field of pharmaceutical production, 11 patents were issued, in 2014 – none, in 2014 – four.
At the same time, Ukrpatent told Interfax-Ukraine that “Ukrainian legislation in the field of protection of rights to utility models and industrial designs does not provide for a qualification examination, so sometimes unfair applicants apply for facilities that are already in the economic flow.”
Ukrpatent reminded that in Ukraine patents for industrial designs and utility models are issued using the declarative system, which does not provide for a qualification examination, which, in the institute’s opinion, corresponds to a fairly widespread international practice.
In this case, the qualification examination can either be conducted, or not conducted, or carried out under a shortened procedure. According to the institute, in 2017, Ukrpatent received 2,480 applications for industrial designs, 9,105 applications for utility models and 4,048 applications for inventions. At the same time, Ukrpatent said that the term “declarative patent” is currently absent in the legislation of Ukraine.
INSTITUTE, INTELLECTUAL PROPERTY, PATENTS, PHARMA PRODUCTION
